Stephanie Pena
Surgical · Natick, MANPI 1558486985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$910
- Astellas Pharma US Inc$513
- Antares Pharma, Inc.$462
- Endo USA, Inc.$283
- Bayer$272
- Tolmar, Inc.$212
- plus $3K from 34 others
What the payments were for
- Travel & lodging$210%
- Food & beverage$4,96994%
- Education$2745%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 35 | $910 |
| Astellas Pharma US Inc | 27 | $513 |
| Antares Pharma, Inc. | 20 | $462 |
| Endo USA, Inc. | 10 | $283 |
| Bayer | 10 | $272 |
| Tolmar, Inc. | 8 | $212 |
| Sumitomo Pharma America, Inc. | 10 | $211 |
| Endo Pharmaceuticals Inc. | 9 | $198 |
| Merck | 7 | $167 |
| Myriad Genetic Laboratories, Inc. | 9 | $162 |
| Ferring Pharmaceuticals Inc. | 6 | $155 |
| Myovant Sciences Inc. | 7 | $149 |
| Pfizer | 7 | $142 |
| Coloplast | 6 | $122 |
| AbbVie(2 entities) | 5 | $106 |
| Medtronic | 2 | $101 |
| 180 Medical, Inc. | 3 | $97 |
| Progenics Pharmaceuticals, Inc. | 4 | $93 |
| Boston Scientific | 4 | $90 |
| Teleflex LLC | 4 | $78 |
| Urovant Sciences Inc | 4 | $68 |
| Axonics, Inc. | 3 | $67 |
| Immunitybio, Inc. | 2 | $61 |
| Novo Nordisk | 2 | $55 |
| Acerus Pharmaceuticals Corporation | 4 | $53 |
| Halozyme Inc | 2 | $46 |
| Dentsply IH AB | 1 | $45 |
| Tolmar Pharmaceuticals, Inc. | 2 | $42 |
| Accord Healthcare, Inc. | 2 | $41 |
| Convatec Inc. | 2 | $38 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Blue Earth Diagnostics | 2 | $27 |
| Novartis | 1 | $26 |
| Agiliti Surgical, Inc. | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| SRS Medical Systems, Inc. | 1 | $16 |
How this compares
$5,264 in reported general payments places this provider in the 95th percentile of 312 surgical providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 121 | $86,675 |
| GemtesaVibegron | 32 | $32,675 |
| Testosterone | 125 | $14,392 |
| Oxybutynin Chloride ErOxybutynin Chloride | 164 | $3,845 |
| Tamsulosin Hcl | 190 | $3,493 |
| Testosterone Cypionate | 108 | $3,289 |
| Methenamine Hippurate | 44 | $2,681 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 86 | $2,388 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $2,288 |
| Cabergoline | 28 | $2,051 |
| Estradiol | 28 | $1,780 |
| NitrofurantoinNitrofurantoin Macrocrystal | 63 | $1,641 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $1,316 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $969 |
| Finasteride | 78 | $930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $513 | $86,675121 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $211 | $32,67532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 surgical providers in Massachusetts.
Other surgical in Natick
- Gregory DeconciliisWaltham$27K
- Lampros MinosWaltham$18K
- Nicolas DesjardinsSomerville$10K
- Robert KenneyChestnut Hill$8K
- Michael LlewellynBoston$8K
- Anargyros SkaliotisNorth Dartmouth$7K
- Caily IrwinCambridge$6K
- Courtney FioreDanvers$6K
- Dana GoldenseBoston$5K
- Jarett LandmanPeabody$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.